Dyne Therapeutics IncNASDAQ:DYN
- LAST PRICE30.6350
- TODAY'S CHANGE (%)-0.4950 (-1.5901%)
- Bid / Lots30.5900/ 16
- Ask / Lots30.6800/ 3
- Open / Previous Close31.2500 / 31.1300
- Day Range
- 52 Week Range
- Volume469,452
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | DYN |
|---|---|---|
| 09:32 ET | 5241 | 31.08 |
| 09:33 ET | 363 | 30.6904 |
| 09:35 ET | 200 | 31.29 |
| 09:37 ET | 1856 | 31.235 |
| 09:39 ET | 326 | 31.18 |
| 09:42 ET | 2000 | 31.145 |
| 09:44 ET | 1782 | 31.235 |
| 09:46 ET | 3975 | 31.205 |
| 09:48 ET | 2130 | 31.24 |
| 09:50 ET | 15409 | 31.04 |
| 09:51 ET | 1350 | 30.96 |
| 09:53 ET | 810 | 30.945 |
| 09:55 ET | 400 | 30.815 |
| 09:57 ET | 200 | 30.845 |
| 10:00 ET | 1953 | 30.93 |
| 10:02 ET | 4177 | 31.06 |
| 10:04 ET | 4700 | 31.025 |
| 10:06 ET | 4400 | 30.96 |
| 10:08 ET | 3400 | 30.55 |
| 10:09 ET | 4201 | 30.21 |
| 10:11 ET | 1533 | 30.475 |
| 10:13 ET | 2597 | 30.775 |
| 10:15 ET | 1465 | 30.65 |
| 10:18 ET | 200 | 30.54 |
| 10:20 ET | 400 | 30.42 |
| 10:22 ET | 100 | 30.31 |
| 10:24 ET | 500 | 30.28 |
| 10:26 ET | 320 | 30.23 |
| 10:27 ET | 1100 | 30.13 |
| 10:29 ET | 580 | 30.1 |
| 10:31 ET | 2354 | 30.31 |
| 10:33 ET | 2646 | 30.305 |
| 10:38 ET | 300 | 30.325 |
| 10:40 ET | 300 | 30.12 |
| 10:42 ET | 900 | 30.02 |
| 10:44 ET | 1300 | 30.22 |
| 10:45 ET | 100 | 30.2 |
| 10:47 ET | 300 | 30.195 |
| 10:49 ET | 1071 | 30.22 |
| 10:51 ET | 600 | 30.33 |
| 10:54 ET | 200 | 30.16 |
| 10:58 ET | 500 | 30.21 |
| 11:00 ET | 1200 | 30.13 |
| 11:02 ET | 258 | 30.06 |
| 11:03 ET | 200 | 30.02 |
| 11:05 ET | 2534 | 30.28 |
| 11:07 ET | 1738 | 30.32 |
| 11:09 ET | 350 | 30.31 |
| 11:12 ET | 5681 | 30.32 |
| 11:14 ET | 1000 | 30.3 |
| 11:16 ET | 1532 | 30.325 |
| 11:18 ET | 804 | 30.18 |
| 11:20 ET | 100 | 30.12 |
| 11:21 ET | 1800 | 30.09 |
| 11:23 ET | 500 | 30.125 |
| 11:25 ET | 400 | 30.24 |
| 11:27 ET | 1143 | 30.11 |
| 11:30 ET | 608 | 30.075 |
| 11:32 ET | 100 | 30.055 |
| 11:34 ET | 1900 | 29.94 |
| 11:36 ET | 200 | 29.89 |
| 11:38 ET | 200 | 29.915 |
| 11:39 ET | 573 | 29.84 |
| 11:41 ET | 1266 | 29.96 |
| 11:43 ET | 200 | 30.05 |
| 11:45 ET | 200 | 30.03 |
| 11:48 ET | 2298 | 29.85 |
| 11:50 ET | 449 | 29.85 |
| 11:52 ET | 645 | 29.84 |
| 11:54 ET | 300 | 29.79 |
| 11:56 ET | 400 | 29.87 |
| 11:57 ET | 283 | 29.89 |
| 11:59 ET | 400 | 29.84 |
| 12:01 ET | 200 | 29.82 |
| 12:03 ET | 1398 | 29.73 |
| 12:06 ET | 800 | 29.85 |
| 12:10 ET | 1540 | 29.89 |
| 12:12 ET | 139 | 29.885 |
| 12:14 ET | 547 | 29.82 |
| 12:15 ET | 804 | 29.86 |
| 12:17 ET | 574 | 29.79 |
| 12:19 ET | 11839 | 30.005 |
| 12:21 ET | 18965 | 30.025 |
| 12:24 ET | 1914 | 29.96 |
| 12:26 ET | 100 | 29.96 |
| 12:28 ET | 2506 | 30 |
| 12:30 ET | 1514 | 30.12 |
| 12:32 ET | 25465 | 30.23 |
| 12:33 ET | 300 | 30.26 |
| 12:35 ET | 704 | 30.32 |
| 12:37 ET | 1338 | 30.22 |
| 12:39 ET | 1100 | 30.28 |
| 12:42 ET | 118 | 30.3 |
| 12:44 ET | 2556 | 30.445 |
| 12:46 ET | 24149 | 30.74 |
| 12:48 ET | 7921 | 30.85 |
| 12:50 ET | 4826 | 30.96 |
| 12:51 ET | 5500 | 30.98 |
| 12:53 ET | 7613 | 30.87 |
| 12:55 ET | 3336 | 30.71 |
| 12:57 ET | 5341 | 30.68 |
| 01:00 ET | 98673 | 30.635 |
Nov 26, 2024
DJ Dyne Therapeutics Initiated at Outperform by RBC Capital, from 5:12AM ET on Tuesday Nov 26, 2024 by Dow Jones
5:12AM ET on Tuesday Nov 26, 2024 by Dow Jones
Nov 13, 2024
DJ Dyne Therapeutics Is Maintained at Buy by Chardan Capital, from 6:43PM ET on Wednesday Nov 13, 2024 by Dow Jones
6:43PM ET on Wednesday Nov 13, 2024 by Dow JonesDJ Dyne Therapeutics Price Target Maintained With a $55.00/Share by HC Wainwright & Co., from 9:45AM ET on Wednesday Nov 13, 2024 by Dow Jones
9:45AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 12, 2024
Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 7:30AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:30AM ET on Tuesday Nov 12, 2024 by Dow Jones*DJ Dyne Therapeutics 3Q Loss/Shr 96c >DYN, from 7:30AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:30AM ET on Tuesday Nov 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Dyne Therapeutics Inc | 3.0B | -8.6x | --- |
Edgewise Therapeutics Inc | 3.0B | -22.1x | --- |
Iovance Biotherapeutics Inc | 2.9B | -6.2x | --- |
Vera Therapeutics Inc | 3.1B | -19.1x | --- |
SpringWorks Therapeutics Inc | 3.1B | -10.7x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Company Information
Dyne Therapeutics Inc. is a clinical-stage muscle disease company. It is focused on advancing life-transforming therapeutics for people living with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that is designed to target the genetic basis of the disease. Using its FORCE platform, it is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker. It also plans to expand its portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases.
Contact Information
- Headquarters
- 1560 Trapelo RoadWALTHAM, MA, United States 02451
- Phone
- 781-786-8230
- Fax
- 781-786-8866
Executives
- Independent Chairman of the Board
- Jason Rhodes
- President, Chief Executive Officer, Director
- John Cox
- Chief Human Resource Officer
- Lucia Celona
- Senior Vice President, Head of Finance and Administration
- Richard Scalzo
- Chief Scientific Officer
- Oxana Beskrovnaya
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.0B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 101.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.10 |
EPS | $-3.56 |
Book Value | $1.49 |
P/E Ratio | -8.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
